Harbour BioMed Advances Global Strategic Collaboration With AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
Monday, November 24, 2025
Harbour BioMed (HBM), a global biopharmaceutical company actively committed to the discovery and development of antibody therapeutics targeting immunology and oncology, has announced a significant advancement in its global strategic collaboration with AstraZeneca. This announcement, made on November 23, 2025, marks a pivotal step in efforts to develop next-generation biotherapeutic solutions, specifically tailored for oncology, and is of particular relevance to the European pharmaceutical landscape as AstraZeneca is a major industry player with substantial operations and commercial presence across Europe.
The collaboration, initially established in March 2025 and now updated, aims to accelerate the discovery and development of innovative antibody-based medicines, including antibody-drug conjugates (ADCs) and T-cell engagers. These cutting-edge modalities are seen as critical to addressing unmet medical needs in oncology, where precision and efficacy are paramount. Under the terms of the agreement, AstraZeneca will continue to nominate discovery programs for Harbour BioMed through 2029, ensuring continuity and scalability in their joint pipeline of novel biotherapeutics. AstraZeneca retains the option to license any of these programs for further development and commercialization—a structure intended to maximize scientific agility and commercial alignment.
This partnership leverages proprietary technology platforms developed by Harbour BioMed, notably the Harbour Mice® system, which facilitates the rapid generation and screening of fully human monoclonal antibodies in both H2L2 and heavy chain-only (HCAb) formats. Harbour BioMed’s innovative HBICE® (HCAb-based bispecific immune cell engager) and HBICA™ (HCAb-based immune cell antagonist) technologies enable highly targeted immune modulation, allowing for the design and development of antibodies that go beyond the limitations of traditional combination therapies. This technological edge has positioned Harbour BioMed as a sought-after partner in the biopharmaceutical industry, especially for organizations in Europe looking to enhance or diversify their R&D pipelines through external innovation.
The advanced collaboration’s structure includes the potential for Harbour BioMed to receive milestone and royalty payments upon successful option exercise and commercialisation of licensed programs. These economics align with standard European industry frameworks for early-stage and translational research partnerships, exemplifying the increasing tendency of large pharmaceutical companies to forge modular, performance-driven alliances with nimble biotech innovators. This model not only accelerates the translation of promising science into clinical candidates but also reduces risk across both early discovery and late-stage development in the highly competitive oncology drug market.
Harbour BioMed has a history of collaborations with AstraZeneca dating back to 2022, with multiple programs advancing successfully, reinforcing mutual trust and operational synergy. Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented that the partnership reflects both organisations’ “commitment to develop innovative biotherapeutics that can address significant unmet medical needs and improve patient outcomes globally.” The European region stands to benefit considerably, as AstraZeneca intends to apply these discoveries within the European regulatory and healthcare systems, potentially accelerating patient access to novel therapies.
This expanded partnership comes amid a surge of global pharma-biotech collaborations, especially in Europe, where regulatory alignment, commitment to innovation, and market size collectively enable rapid adoption of advanced therapies in oncology. Such strategic collaborations pave the way for streamlined research, reduced time-to-market for therapeutic assets, and the establishment of new standards in personalized medicine. European pharma executives, researchers, drug manufacturers, and regulatory bodies are expected to watch the progress of this collaboration closely, as it exemplifies current trends shaping the European biopharma ecosystem in 2025.
